Combined inhibition of mTOR and CDK4/6 is required for optimal blockade of E2F function and long term growth inhibition in estrogen receptor positive breast cancer

被引：0
|
作者：
Oelmann, Elisabeth
Michaloglou, Chrysiis
Crafter, Claire
Siersbaek, Rasmus
Delpuech, Oona
Curven, Jon
Carnevalli, Larissa
Staniszweska, Anna
Polanska, Urszula
Cheraghchi-Bashi, Azadeh
Lawson, Mandy
Chernukhin, Igor
McEwen, Robert
Carroll, Jason
Cosulich, Sabina
机构：
[1] AstraZeneca, Cambridge, Cambs, England
[2] CRUK Cambridge Inst, Cambridge, Cambs, England
[3] Univ Bradford, Bradford, Cheshire, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD4-04
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Synergistic targeting of CDK4/6 and BCL-2 pathways in estrogen receptor positive breast cancer
    Whittle, J. R.
    Vaillant, F.
    Policheni, A. N.
    Liu, K.
    Pal, B.
    Giner, G.
    Fernandez, K.
    Gray, D. H.
    Caldon, C. E.
    Smyth, G. K.
    Visvader, J. E.
    Lindeman, G. J.
    CANCER RESEARCH, 2019, 79 (04)
  • [22] Combined inhibition of CDK2 and CDK4/6 overcomes acquired resistance to CDK4/6 inhibitors in breast cancer via RB-independent pathway
    Pandey, Kamal
    CANCER RESEARCH, 2020, 80 (16)
  • [23] CDK4/6 BLOCKADE IMPROVES THE EFFICACY OF PI3K INHIBITION IN BREAST CANCER
    不详
    CANCER DISCOVERY, 2014, 4 (09) : 983 - 983
  • [24] Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer (vol 76, pg 2301, 2016)
    Herrera-Abreu, Maria Teresa
    Palafox, Marta
    Asghar, Uzma
    Rivas, Martin A.
    Cutts, Rosalind J.
    Garcia-Murillas, Isaac
    Pearson, Alex
    Guzman, Marta
    Rodriguez, Olga
    Grueso, Judit
    Bellet, Meritxell
    Cortes, Javier
    Elliott, Richard
    Pancholi, Sunil
    Lord, Christopher J.
    Baselga, Jose
    Dowsett, Mitch
    Martin, Lesley-Ann
    Turner, Nicholas C.
    Serra, Violeta
    CANCER RESEARCH, 2016, 76 (19) : 5907 - 5907
  • [25] MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
    Neil Portman
    Heloisa H. Milioli
    Sarah Alexandrou
    Rhiannon Coulson
    Aliza Yong
    Kristine J. Fernandez
    Kee Ming Chia
    Ensar Halilovic
    Davendra Segara
    Andrew Parker
    Sue Haupt
    Ygal Haupt
    Wayne D. Tilley
    Alex Swarbrick
    C. Elizabeth Caldon
    Elgene Lim
    Breast Cancer Research, 22
  • [26] MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
    Lim, Elgene
    Milioli, Heloisa H.
    Alexandrou, Sarah
    Coulson, Rhiannon
    Yong, Aliza
    Fernandez, Kristine J.
    Chia, KeeMing
    Halilovic, Ensar
    Segara, Davendra
    Parker, Andrew
    Haupt, Sue
    Haupt, Ygal
    Tilley, Wayne D.
    Swarbrick, Alex
    Caldon, Elizabeth C.
    Portman, Neil
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 110 - 110
  • [27] MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
    Portman, Neil
    Milioli, Heloisa H.
    Alexandrou, Sarah
    Coulson, Rhiannon
    Yong, Aliza
    Fernandez, Kristine J.
    Chia, Kee Ming
    Halilovic, Ensar
    Segara, Davendra
    Parker, Andrew
    Haupt, Sue
    Haupt, Ygal
    Tilley, Wayne D.
    Swarbrick, Alex
    Caldon, C. Elizabeth
    Lim, Elgene
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [28] Overcoming resistance to inhibitors of CDK4/6 and BET in estrogen receptor-positive breast cancer
    Cosin, Marc
    Tian, Tian
    Oliveros, Winona
    Kharenko, Olesya A.
    van der Horst, Edward H.
    Patel, Reena G.
    Calosing, Cyrus
    Campeau, Eric
    Jahagirdar, Ravi
    Lakhotia, Sanjay
    Mele, Marta
    Palafox, Marta
    Arribas, Joaquin
    Oliveira, Mafalda
    Saura, Cristina
    Serra, Violeta
    Peiro, Sandra
    CANCER RESEARCH, 2020, 80 (16)
  • [29] CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects
    Wekking, Demi
    Leoni, Vera Piera
    Lambertini, Matteo
    Dessi, Mariele
    Pretta, Andrea
    Cadoni, Andrea
    Atzori, Luigi
    Scartozzi, Mario
    Solinas, Cinzia
    CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 75 : 57 - 64
  • [30] CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer A network meta-analysis
    Huang, Hong-Wei
    Huang, Li-Sheng
    Xu, Qi-Ni
    Wang, Hong-Biao
    Li, Xu-Yuan
    Lin, Jia-Zhou
    MEDICINE, 2019, 98 (01)
12345